Table of Contents

Cancer-related neuropathic pain is common, with 40% of cancer patients experiencing neuropathic pain. Cancer pain has traditionally been treated with opioids, but adjuvant therapy such as Gabapentin is now effectively being used to more greatly reduce cancer-related pain compared to opioid monotherapy. Objective: To determine the effectiveness of the use of anti-neuropathic pain treatments in cancer pain patients at Zainoel Abidin General Hospital Banda Aceh. Study group: The samples in this study was 71 respondents who experienced cancer pain from August to December 2018. Methods: This study used prospective observational analytic with the Numeric Rating Scale (NRS) to measure pain intensity, a DN-4 questionnaire to assess the type of pain, and an overview of the types of anti-neuropathic pain drugs used and assessed for a maximum of 10 days to see a decrease in pain. Results: From 71 respondents, 50 respondents (70.4%) experiencing neuropathic pain and 21 respondents (29.6%) experiencing nociceptic pain. A combination of gabapentin and paracetamol, as well as gabapentin, opioid and paracetamol had highest mean in reducing pain, which was 5.4000, it was more effective compared to a combination of opioids, NSAIDs and paracetamol, which was 2.4000. After the Post Hoc Duncan Test, we also found gabapentin and gabapentin combination showed significant results in reducing pain compared to opioid and opioid combination in cancer pain patients. Conclusion: Gabapentin is the most effective method of reducing pain in cancer pain patients at Zainoel Abidin General Hospital Banda Aceh.

Keywords: Cancer pain, anti-neuropathic pain, opioids, gabapentin.